exhibit161

Exhibit 16.1

July 26, 2023

U.S. Securities and Exchange Commission

100 F Street, NE

Washington,

D.C. 20549

We have read

Vaxxinity,

Inc.’s statements included in Item 4.01

of its Current Report Form 8-K dated July 26, 2023

and agree with those statements concerning our firm. We

have no basis to agree or disagree with other statements of

the registrant contained therein.

/s/ Armanino LLP